Accordingly, in three patients with cholangiocarcinoma treated with BGJ398 (phase II study, NCT02160041) the FGFR2-BICC1 fusion decreased in cfDNA upon initiation of treatment and increased at the time of radiological progression (81). Here, BICC1 is linked to cholangiocarcinoma.